Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

including Bausch + Lomb contact lens brands such as Bausch + Lomb INFUSE ®, Bausch + Lomb ULTRA ® and Biotrue ® ONEday. Over-the-counter products will include LUMIFY ® redness reliever eye ...

including Biotrue and SofLens. We are still impressed at the overall performance and believe the firm's share in the contact lens market slightly increased. Miebo and Xiidra, Bausch & Lomb's dry ...

When he was twenty years old in 1849, he emigrated to the United States. Lomb worked as a carpenter before he joined John Jacob Bausch, the owner of a retail optical shop in Rochester. Lomb invested ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

Bausch & Lomb is one of the largest vision care companies ... We expect patents and product superiority of Biotrue eye drops, Lumify, and PreserVision to secure Bausch as a leader in the over ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

Citi raised the firm’s price target on Bausch + Lomb (BLCO) to $24 from $20 and keeps a Buy rating on the shares. The firm says management “delivered a solid quarter with not much to balk at.” The ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target of $23.00. Yi Chen has given his Buy rating due to a ...